Compare RGEN & PPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGEN | PPC |
|---|---|---|
| Founded | 1981 | 1946 |
| Country | United States | United States |
| Employees | N/A | 52100 |
| Industry | Medical/Dental Instruments | Meat/Poultry/Fish |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 9.7B |
| IPO Year | 1995 | 1997 |
| Metric | RGEN | PPC |
|---|---|---|
| Price | $121.61 | $38.63 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 3 |
| Target Price | ★ $173.09 | $44.33 |
| AVG Volume (30 Days) | 767.3K | ★ 839.1K |
| Earning Date | 05-27-2026 | 05-15-2026 |
| Dividend Yield | N/A | ★ 20.61% |
| EPS Growth | ★ 286.96 | N/A |
| EPS | 0.86 | ★ 4.54 |
| Revenue | $141,236,000.00 | ★ $18,497,553,000.00 |
| Revenue This Year | $14.11 | $2.39 |
| Revenue Next Year | $14.71 | $1.82 |
| P/E Ratio | $139.37 | ★ $8.97 |
| Revenue Growth | ★ 35.10 | 3.46 |
| 52 Week Low | $102.97 | $35.73 |
| 52 Week High | $175.77 | $56.73 |
| Indicator | RGEN | PPC |
|---|---|---|
| Relative Strength Index (RSI) | 33.82 | 33.57 |
| Support Level | $121.25 | $36.80 |
| Resistance Level | $132.51 | $38.86 |
| Average True Range (ATR) | 6.58 | 1.10 |
| MACD | -0.05 | -0.41 |
| Stochastic Oscillator | 15.23 | 0.00 |
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
Pilgrim's Pride is the second-largest poultry producer in the US (59% of 2024 sales), the UK (29% including other European sales), and Mexico (12%). Its UK and European arm also includes pork operations from the 2019 acquisition of Tulip. Pilgrim's sells to chain restaurants, food processors, food distributors, and retail chains. Most of its US and Mexican sales come from fresh chicken, while prepared chicken and pork constitute most of its UK and European sales. JBS owns more than 80% of Pilgrim's Pride's outstanding shares, though it failed to acquire the remaining stake in 2021 after a special board committee deemed JBS's offer undervalued Pilgrim's Pride.